echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Lancet Neurology: Safety and efficacy of propranolol in the treatment of familial cavernous hemangioma

    Lancet Neurology: Safety and efficacy of propranolol in the treatment of familial cavernous hemangioma

    • Last Update: 2023-01-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Observations in patients with cavernous malformations of the brain, as well as in preclinical models of this disease, suggest that β the receptor blocker propranolol may reduce the risk of intracerebral hemorrhage.

    Academics from Italy aimed to assess the safety and efficacy of long-term treatment with propranolol to reduce the incidence
    of symptomatic intracerebral hemorrhage or focal neurological dysfunction in patients with familial cavernous malformations.

    The researchers conducted a randomized, open-label, double-blind, Phase II trial (Treat_CCM)
    at six national rare disease reference centers in Italy.
    Patients aged 18 years or older with symptomatic familial cavernous malformation were randomly assigned (2:1) to receive oral propranolol (20-320 mg per day) plus standard care (intervention group), or standard care alone (control group) for 24 months
    .
    Clinical evaluation and 3TMRI studies were performed at baseline, 12 months, and 24 months, and the primary results were symptomatic intra-brain hemorrhage or focal neurological deficit
    newly developed within 24 months that could be attributed to cavernous malformations.

    Between 11 April 2018 and 5 December 2019, 95 people were assessed for eligibility and 83 were selected, of whom 57 were assigned to propranolol plus standard care and 26 to standard care alone
    .
    The mean age of participants was 46 years (SD 15); Forty-eight (58%) were female and 35 (42%) were male
    .
    The incidence of symptomatic intracerebral haemorrhage or focal neurologic deficit was 1.
    7 per 100 person-years (95% CI 1.
    4 to 2.
    0) in the standard care group and 3.
    9 per 100 person-years (3.
    1 to 4.
    7) in the standard care group alone (univariate HR = 0.
    43, 80% CI 0.
    18 to 0.
    98).

    According to the predetermined criteria, the results suggest that propranolol shows efficacy
    .
    There was no difference
    in the incidence of hospitalization between groups.

    In summary, propranolol is safe in this population and well tolerated
    .
    Propranolol may be beneficial in reducing the rate of
    clinical events in patients with symptomatic familial cavernous malformations.

     

    References:

    Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.